U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07550777) titled 'Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab' on Feb. 19.
Brief Summary: Bevacizumab, an anti-VEGF (vascular endothelial growth factor) agent used in the treatment of diabetic retinopathy and macular edema associated with retinal vein occlusion, is commonly administered in ophthalmology clinics through intravitreal injection. The systemic use of bevacizumab has been associated with serious conditions such as thromboembolism and bleeding. Although intravitreal bevacizumab is administered in smaller amounts and has limited systemic circulation, it requires repeated injections over a long ...